ACP5

Across TCGA pan-cancer cohorts, ACP5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ACP5 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACP5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACP5 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where ACP5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.242	0.684	.013	13	view →
UCEC	DFS	Quartile	All	0.827	1.000	.018	8	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	6	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ACP5–LUAD (OS)

Open the LUAD breakdown →